ArticleAnnals of hematology2025

Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies.

Zhihui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.